Published in PLoS Pathog on May 16, 2013
The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res (2014) 1.07
Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. J Clin Invest (2014) 0.99
Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies. Front Microbiol (2014) 0.96
Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423. PLoS Pathog (2014) 0.96
Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies. Clin Dev Immunol (2013) 0.95
Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies. J Virol (2014) 0.95
Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzee. J Virol (2014) 0.93
Discrete conformations of epitope II on the hepatitis C virus E2 protein for antibody-mediated neutralization and nonneutralization. Proc Natl Acad Sci U S A (2014) 0.92
Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex. J Virol (2014) 0.87
Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design. Curr Opin Virol (2015) 0.86
Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell (2015) 0.86
CD81 and hepatitis C virus (HCV) infection. Viruses (2014) 0.84
Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses (2015) 0.84
Complexes of neutralizing and non-neutralizing affinity matured Fabs with a mimetic of the internal trimeric coiled-coil of HIV-1 gp41. PLoS One (2013) 0.83
A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies. J Virol (2016) 0.80
Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding. Sci Rep (2015) 0.80
HCV E2 core structures and mAbs: something is still missing. Drug Discov Today (2014) 0.79
Prediction of linear B-cell epitopes of hepatitis C virus for vaccine development. BMC Med Genomics (2015) 0.78
Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity. Hepatology (2016) 0.78
Viral evasion and challenges of hepatitis C virus vaccine development. Curr Opin Virol (2016) 0.77
Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies. Expert Rev Vaccines (2016) 0.77
Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen. Proc Natl Acad Sci U S A (2016) 0.77
The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs. Hepatology (2017) 0.76
Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection. J Virol (2016) 0.76
Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice. Hepatology (2016) 0.75
Delineation of autoantibody repertoire through differential proteogenomics in hepatitis C virus-induced cryoglobulinemia. Sci Rep (2016) 0.75
Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2. MBio (2017) 0.75
A view of the E2-CD81 interface at the binding site of a neutralizing antibody against hepatitis C virus. J Virol (2014) 0.75
Structure-Based Design of Hepatitis C Virus Vaccines that Elicit Neutralizing Antibody Responses to a Conserved Epitope. J Virol (2017) 0.75
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
Features and development of Coot. Acta Crystallogr D Biol Crystallogr (2010) 89.46
Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr (2005) 61.38
Inference of macromolecular assemblies from crystalline state. J Mol Biol (2007) 44.95
Somatic generation of antibody diversity. Nature (1983) 28.06
Shape complementarity at protein/protein interfaces. J Mol Biol (1993) 10.40
NPS@: network protein sequence analysis. Trends Biochem Sci (2000) 9.68
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology (2005) 9.39
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res (2008) 5.42
Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci U S A (2004) 5.15
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2006) 3.44
Data processing and analysis with the autoPROC toolbox. Acta Crystallogr D Biol Crystallogr (2011) 3.41
A genetically humanized mouse model for hepatitis C virus infection. Nature (2011) 3.15
Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A (2007) 3.13
Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med (2010) 3.09
PIC: Protein Interactions Calculator. Nucleic Acids Res (2007) 3.02
The role of somatic hypermutation in the generation of antibody diversity. Science (1989) 2.55
The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog (2010) 2.28
Antiviral strategies in hepatitis C virus infection. J Hepatol (2012) 2.25
Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology (2009) 1.89
V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood (2001) 1.79
Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog (2012) 1.79
Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc Natl Acad Sci U S A (2012) 1.74
Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci U S A (2009) 1.72
Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol (2008) 1.68
Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci U S A (2007) 1.66
A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry. J Virol (2006) 1.62
Identification of the hepatitis C virus E2 glycoprotein binding site on the large extracellular loop of CD81. J Virol (2002) 1.58
Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology (2008) 1.55
Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. J Gen Virol (2000) 1.55
New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut (2012) 1.50
Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J Virol (2010) 1.41
Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog (2012) 1.35
Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med (1998) 1.29
In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A (2008) 1.25
Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J Virol (2012) 1.24
Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J Exp Med (2012) 1.23
Structure of a pestivirus envelope glycoprotein E2 clarifies its role in cell entry. Cell Rep (2012) 1.18
Structure of hepatitis C virus envelope glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33. J Virol (2012) 1.18
Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology (2005) 1.17
Crystal structure of glycoprotein C from Rift Valley fever virus. Proc Natl Acad Sci U S A (2013) 1.15
Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol (2011) 1.13
Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J Virol (2012) 1.12
Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion. J Biol Chem (2011) 1.04
Efficient method for production of high yields of Fab fragments in Drosophila S2 cells. Protein Eng Des Sel (2010) 0.89
Hepatitis C and liver transplantation: enhancing outcomes and should patients be retransplanted. Clin Liver Dis (2008) 0.86
Association of anti-E1E2 antibodies with spontaneous recovery or sustained viral response to therapy in patients infected with hepatitis C virus. Hepatology (2010) 0.84
Production of recombinant antibodies in Drosophila melanogaster S2 cells. Methods Mol Biol (2012) 0.81
Structural biology of hepatitis C virus. Hepatology (2004) 3.40
Characterization of reemerging chikungunya virus. PLoS Pathog (2007) 3.22
A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med (2006) 3.12
Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrob Agents Chemother (2004) 2.89
Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science (2009) 2.71
The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog (2010) 2.28
Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals. J Biol Chem (2005) 2.02
Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J Virol (2004) 1.98
Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med (2012) 1.94
Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol (2008) 1.91
Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol (2003) 1.89
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol (2009) 1.87
Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog (2012) 1.79
The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol (2007) 1.69
Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. Virology (2002) 1.67
Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol (2006) 1.66
Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol (2008) 1.63
Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol (2010) 1.63
Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein. J Biol Chem (2008) 1.61
Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J Virol (2005) 1.53
Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. Structure (2012) 1.43
Structure of a core fragment of glycoprotein H from pseudorabies virus in complex with antibody. Proc Natl Acad Sci U S A (2010) 1.38
Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J Virol (2004) 1.37
In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A (2008) 1.25
Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J Virol (2012) 1.24
Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells. Virology (2005) 1.22
Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. J Virol (2010) 1.19
Characterization of a membrane-associated trimeric low-pH-induced Form of the class II viral fusion protein E from tick-borne encephalitis virus and its crystallization. J Virol (2004) 1.19
Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus. EMBO J (2011) 1.17
The nine C-terminal amino acids of the respiratory syncytial virus protein P are necessary and sufficient for binding to ribonucleoprotein complexes in which six ribonucleotides are contacted per N protein protomer. J Gen Virol (2007) 1.15
Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J Virol (2009) 1.13
Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J Virol (2012) 1.12
Class II enveloped viruses. Cell Microbiol (2011) 1.12
Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody. J Virol (2003) 1.09
Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. J Immunol (2006) 1.05
Molecular and structural bases for the antigenicity of VP2 of infectious bursal disease virus. J Virol (2007) 1.04
Neutralizing antibody response to hepatitis C virus. Viruses (2011) 1.03
A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope. J Virol (2008) 1.02
Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies. Hepatology (2013) 0.99
Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. J Clin Invest (2014) 0.99
Transient activation of the PI3K-AKT pathway by hepatitis C virus to enhance viral entry. J Biol Chem (2012) 0.97
Antibody-dependent enhancement of hepatitis C virus infection. J Virol (2007) 0.96
An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. Hepatology (2013) 0.96
Crystal structure of a human autoimmune complex between IgM rheumatoid factor RF61 and IgG1 Fc reveals a novel epitope and evidence for affinity maturation. J Mol Biol (2007) 0.96
Structure of the Triatoma virus capsid. Acta Crystallogr D Biol Crystallogr (2013) 0.93
Purification and crystallization reveal two types of interactions of the fusion protein homotrimer of Semliki Forest virus. J Virol (2004) 0.93
Efficient method for production of high yields of Fab fragments in Drosophila S2 cells. Protein Eng Des Sel (2010) 0.89
Structural elucidation of critical residues involved in binding of human monoclonal antibodies to hepatitis C virus E2 envelope glycoprotein. Biochim Biophys Acta (2008) 0.89
Structure-based mutational analysis of the highly conserved domain IV of glycoprotein H of pseudorabies virus. J Virol (2012) 0.89
Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a. Hepatology (2014) 0.89
Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. J Biol Chem (2011) 0.88
Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships. J Gen Virol (2011) 0.85
Scaffolds for protein crystallisation. Acta Crystallogr D Biol Crystallogr (2002) 0.84
Characterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entry. J Virol (2012) 0.84
Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer. J Oncol (2010) 0.84
Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses. J Biosci (2003) 0.82
SnapShot: Viral and eukaryotic protein fusogens. Cell (2012) 0.81
Virus entry: old viruses, new receptors. Curr Opin Virol (2012) 0.81
Incomplete humoral immunity against hepatitis C virus is linked with distinct recognition of putative multiple receptors by E2 envelope glycoprotein. J Immunol (2004) 0.80
Isolation of Fully Human Antagonistic RON Antibodies Showing Efficient Block of Downstream Signaling and Cell Migration. Transl Oncol (2011) 0.80
Hepatitis C virus e2 protein ectodomain is essential for assembly of infectious virions. Int J Hepatol (2010) 0.77
T helper type 2 bias and type 17 suppression in primary dengue virus infection in infants and young children. Trans R Soc Trop Med Hyg (2013) 0.76
Epitope mapping of human monoclonal antibodies recognizing conformational epitopes within HTLV type 1 gp46, employing HTLV type 1/2 envelope chimeras. AIDS Res Hum Retroviruses (2002) 0.76
Virology: holed up in a natural crystal. Nature (2007) 0.76
Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol (2015) 0.76
The hepatitis C virus E1 glycoprotein undergoes productive folding but accelerated degradation when expressed as an individual subunit in CHO cells. PLoS One (2011) 0.75
Macromolecular assemblages. Curr Opin Struct Biol (2011) 0.75
Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol (2015) 0.75
Macromolecular assemblies. Curr Opin Struct Biol (2013) 0.75
Virus structure and function. Curr Opin Virol (2013) 0.75
Antibody light chain-catalyzed hydrolysis of a hepatitis C virus peptide. Bioorg Med Chem Lett (2004) 0.75